
-
Amneal Pharmaceuticals Inc. NasdaqGS:AMRX Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Location: 400 Crossing Boulevard, Bridgewater, NJ, 08807, United States | Website: https://www.amneal.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
4.878B
Cash
61.63M
Avg Qtr Burn
N/A
Short % of Float
3.21%
Insider Ownership
46.75%
Institutional Own.
44.26%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PEMRYDI RTU® Details Small cell lung cancer, Malignant pleural/peritoneal mesothelioma | Approved Update | |
RELEUKO® (filgrastim-ayow) Details Chemotherapy-induced neutropenia | Approved Quarterly sales | |
Approved Quarterly sales | ||
Xyrem® (sodium oxybate) Generic Details Narcolepsy | Approved Quarterly sales | |
OTC NARCAN® HCI Nasal Spray Details Opioid overdose | Approved Quarterly sales | |
BORUZU (Bortezomib) Details Multiple myeloma, Mantle cell lymphoma | Approved Quarterly sales | |
Potassium Phosphates Injection IV Bags Details Hypophosphatemia | Approved Quarterly sales | |
Lisdexamfetamine Dimesylate Details Attention deficit hyperactivity disorder | Approved Quarterly sales | |
CREXONT® (Carbidopa & Levodopa) (IPX203) Details Parkinson's disease | Approved Quarterly sales | |
Denosumab Biosimilars Details Osteoporosis | PDUFA Approval decision |